# GLP-1s for $50 a Month? 14 Million Medicare Recipients May Be Eligible
Up to 14 million Medicare recipients now qualify for GLP-1 medications like Ozempic and Wegovy at a capped cost of $50 per month. This expansion represents a major shift in access to drugs that help manage type 2 diabetes and weight loss.
Medicare's negotiated prices for GLP-1 receptor agonists take effect in 2026. The $50 monthly cap applies to beneficiaries who reach the catastrophic coverage phase, where Medicare covers 80 percent of drug costs. Eligible patients include those with type 2 diabetes and individuals with cardiovascular disease or obesity.
For context, GLP-1 medications normally cost $900 to $1,300 monthly without insurance. The previous out-of-pocket maximum for Medicare Part D was capped at $7,400 annually. The new cap dramatically lowers barriers for older adults who need these drugs but previously couldn't afford them.
Dr. James Wu, an endocrinologist at Stanford Medicine, notes that affordability has been the primary barrier preventing seniors from accessing GLP-1s. "This policy change addresses a real gap in care," Wu explains. Many older adults with type 2 diabetes stopped medication due to cost, leading to worse health outcomes.
Eligibility requires enrollment in a Medicare Part D prescription drug plan. Beneficiaries should review their current coverage to understand how GLP-1s fit into their deductible and out-of-pocket limits. Those with Medicaid coverage, employer-sponsored retiree plans, or Veterans Affairs benefits should check their own negotiated prices, which may differ.
The Centers for Medicare and Medicaid Services (CMS) also capped prices for other high-cost drugs including blood thin